K
Kai W. Wucherpfennig
Researcher at Harvard University
Publications - 278
Citations - 31847
Kai W. Wucherpfennig is an academic researcher from Harvard University. The author has contributed to research in topics: T cell & T-cell receptor. The author has an hindex of 82, co-authored 250 publications receiving 24671 citations. Previous affiliations of Kai W. Wucherpfennig include Broad Institute & Howard Hughes Medical Institute.
Papers
More filters
Journal ArticleDOI
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Peng Jiang,Shengqing Gu,Deng Pan,Jingxin Fu,Avinash Das Sahu,Xihao Hu,Ziyi Li,Nicole Traugh,Xia Bu,Bo Li,Bo Li,Jun Liu,Gordon J. Freeman,Myles Brown,Kai W. Wucherpfennig,X. Shirley Liu +15 more
TL;DR: An algorithm-selected gene signature focused on tumor immune evasion and suppression predicts response to immune checkpoint blockade in melanoma, exceeding the accuracy of current clinical biomarkers.
Journal ArticleDOI
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott,Zhuting Hu,Derin B. Keskin,Derin B. Keskin,Sachet A. Shukla,Sachet A. Shukla,Jing Sun,David J. Bozym,Wandi Zhang,Adrienne M. Luoma,Anita Giobbie-Hurder,Lauren Peter,Christina Chen,Oriol Olive,Todd A. Carter,Shuqiang Li,David J. Lieb,Thomas Eisenhaure,Evisa Gjini,Jonathan Stevens,William J. Lane,Indu Javeri,Kaliappanadar Nellaiappan,Andres M. Salazar,Heather Daley,Michael S. Seaman,Elizabeth I. Buchbinder,Elizabeth I. Buchbinder,Charles H. Yoon,Maegan Harden,Niall J. Lennon,Stacey Gabriel,Scott J. Rodig,Scott J. Rodig,Dan H. Barouch,Dan H. Barouch,Dan H. Barouch,Jon C. Aster,Jon C. Aster,Gad Getz,Gad Getz,Kai W. Wucherpfennig,Donna Neuberg,Jerome Ritz,Jerome Ritz,Eric S. Lander,Eric S. Lander,Edward F. Fritsch,Edward F. Fritsch,Nir Hacohen,Nir Hacohen,Catherine J. Wu +51 more
TL;DR: The feasibility, safety, and immunogenicity of a vaccine that targets up to 20 predicted personal tumour neoantigens is demonstrated and a strong rationale for further development of this approach, alone and in combination with checkpoint blockade or other immunotherapies is provided.
Journal ArticleDOI
Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein
TL;DR: In this paper, structural similarity between viral T cell epitopes and self-peptides could lead to the induction of an autoaggressive T cell response based on the structural requirements for both MHC class 11 binding and TCR recognition of an immunodominant myelin basic protein (MBP) peptide.
Journal ArticleDOI
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Derin B. Keskin,Annabelle J. Anandappa,Jing Sun,Itay Tirosh,Nathan Mathewson,Shuqiang Li,Giacomo Oliveira,Anita Giobbie-Hurder,Kristen Felt,Evisa Gjini,Sachet A. Shukla,Zhuting Hu,Letitia Li,Phuong M. Le,Rosa Lundbye Allesøe,Rosa Lundbye Allesøe,Alyssa R. Richman,Monika S. Kowalczyk,Sara Abdelrahman,Jack Geduldig,Sarah Charbonneau,Kristine Pelton,J. Bryan Iorgulescu,Liudmila Elagina,Wandi Zhang,Oriol Olive,Christine McCluskey,Lars Rønn Olsen,Jonathan Stevens,William J. Lane,Andres M. Salazar,Heather Daley,Patrick Y. Wen,E. Antonio Chiocca,Maegan Harden,Niall J. Lennon,Stacey Gabriel,Gad Getz,Eric S. Lander,Aviv Regev,Jerome Ritz,Donna Neuberg,Scott J. Rodig,Keith L. Ligon,Mario L. Suvà,Kai W. Wucherpfennig,Nir Hacohen,Edward F. Fritsch,Kenneth J. Livak,Patrick A. Ott,Catherine J. Wu,David A. Reardon +51 more
TL;DR: It is demonstrated that a strategy that uses multi-epitope, personalized neoantigen vaccination, which has previously been tested in patients with high-risk melanoma, is feasible for tumours such as glioblastoma, which typically have a relatively low mutation load and an immunologically ‘cold’ tumour microenvironment.
Journal ArticleDOI
Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation
Thomas Korn,Jayagopala Reddy,Wenda Gao,Estelle Bettelli,Amit Awasthi,Troels R. Petersen,B Thomas Bäckström,Raymond A. Sobel,Raymond A. Sobel,Kai W. Wucherpfennig,Terry B. Strom,Mohamed Oukka,Vijay K. Kuchroo +12 more
TL;DR: The data suggest that in order for CD4+Foxp3+ T-reg to effectively control autoimmune reactions in the target organ, it may also be necessary to control tissue inflammation.